Company intelligence / Profile preview

Clovis Oncology

Boulder, Colorado, United Statesorpha.net ↗

Ownership: Private
Development stage: Commercial

Overview

Clovis Oncology developed Rubraca (rucaparib) for ovarian and prostate cancer, which received FDA approval. The company also had FAP-2286, a peptide-targeted radionuclide therapy candidate in Phase 1/2 trials. The company filed for bankruptcy in December 2022.

Therapeutic areas: Oncology
Modalities: Small moleculesPeptide-targeted radionuclide therapy (PTRT)
Industry: Biotech

Drug pipeline

5 assets

rucaparib

Approved

4 more assets in the full pipeline.

Request access →

Partnerships

Clavis PharmaBristol-Myers Squibb (Opdivo combination trials)

Beyond the preview

Go deeper on Clovis Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Clovis Oncology.

Explore the full profile